436 Results for "

CDK2

" in MedChemExpress (MCE) Product Catalog:
Products (436)

436 Results for "CDK2" in MCE Product Catalog:

73
73 Publications Verification
Cat. No.: HY-12529
CAS No.: 872573-93-8
Purity:  98.68%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-10492
CAS No.: 779353-01-4
Purity:  99.80%
Synonyms: SCH 727965
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively .
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-10005
CAS No.: 146426-40-6
Purity:  99.73%
Synonyms: HMR-1275; Alvocidib; L86-8275
Target:  

CDK Autophagy HIV Apoptosis

Research Areas:  

Cancer

Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-10006
CAS No.: 131740-09-5
Purity:  99.73%
Synonyms: Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride
Target:  

CDK Autophagy HIV

Research Areas:  

Cancer

Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-12214A
CAS No.: 1263373-43-8
Purity:  99.60%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC50 values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-18174
CAS No.: 1234015-52-1
Synonyms: LY2606368
Research Areas:  

Cancer

Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity [2].
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-18174A
CAS No.: 1234015-54-3
Synonyms: LY2606368 dihydrochloride
Research Areas:  

Cancer

Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dihydrochloride inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity [2].
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-18174E
CAS No.: 1234015-58-7
Synonyms: LY2606368 dimesylate
Research Areas:  

Cancer

Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity [2].
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-30237
CAS No.: 186692-46-6
Synonyms: Seliciclib; CYC202
Target:  

CDK

(R)-Roscovitine (Seliciclib) is an orally bioavailable, selective and BBB-permeable CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-50943
CAS No.: 902135-91-5
Target:  

CDK Apoptosis

Research Areas:  

Cancer

AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-50940
CAS No.: 844442-38-2
Synonyms: AT7519M
Target:  

CDK Apoptosis

Research Areas:  

Cancer

AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-50940A
CAS No.: 1431697-85-6
Synonyms: AT7519M TFA
Target:  

CDK

Research Areas:  

Cancer

AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-15532
CAS No.: 891494-63-6
Purity:  99.81%
Synonyms: MK-8776
Research Areas:  

Cancer

SCH900776 (MK-8776) is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with an IC50 of 3 nM. SCH900776 shows 50- and 500-fold selectivity over CDK2 and Chk2, respectively [2].
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-101257
CAS No.: 1957203-01-8
Purity:  98.79%
Target:  

CDK

Research Areas:  

Cancer

YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-101257B
CAS No.: 2748220-93-9
Purity:  99.74%
Target:  

CDK

Research Areas:  

Cancer

YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-12302
CAS No.: 142273-20-9
Purity:  98.20%
Synonyms: 9-Bromopaullone; NSC-664704
Target:  

CDK GSK-3

Research Areas:  

Cancer

Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-10012
CAS No.: 602306-29-6
Purity:  99.91%
Target:  

CDK

Research Areas:  

Cancer

AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC50s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-13650
CAS No.: 165668-41-7
Purity:  99.80%
Synonyms: E 7070
Research Areas:  

Cancer

Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 [2].
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-15154
CAS No.: 212779-48-1
Purity:  99.88%
Synonyms: Compound 52
Target:  

CDK

Research Areas:  

Cancer

NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p [2].
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-124719
CAS No.: 1402452-15-6
Purity:  99.82%
Target:  

PI3K mTOR GSK-3 CDK

Research Areas:  

Cancer

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer .
loading...
    loading...